Gut mucosal DAMPs in IBD: from mechanisms to therapeutic implications

Endogenous damage-associated molecular patterns (DAMPs) are released during tissue damage and have increasingly recognized roles in the etiology of many human diseases. The inflammatory bowel diseases (IBD), ulcerative colitis (UC) and Crohn's disease (CD), are immune-mediated conditions where...

Full description

Saved in:
Bibliographic Details
Published inMucosal immunology Vol. 9; no. 3; pp. 567 - 582
Main Authors Boyapati, R K, Rossi, A G, Satsangi, J, Ho, G-T
Format Journal Article
LanguageEnglish
Published United States Nature Publishing Group 01.05.2016
Subjects
Animals
Biomarkers - metabolism
Crohn's disease
Etiology
Humans
Inflammation - immunology
Inflammatory bowel diseases
Inflammatory Bowel Diseases - immunology
Inflammatory Bowel Diseases - therapy
Intestinal Mucosa - immunology
Intestine
Leukocyte L1 Antigen Complex - metabolism
Molecular Targeted Therapy
Mucosa
Receptors, Pattern Recognition - metabolism
Translational Research, Biomedical
Ulcerative colitis
Online AccessGet full text

Cover

More Information
Summary:Endogenous damage-associated molecular patterns (DAMPs) are released during tissue damage and have increasingly recognized roles in the etiology of many human diseases. The inflammatory bowel diseases (IBD), ulcerative colitis (UC) and Crohn's disease (CD), are immune-mediated conditions where high levels of DAMPs are observed. DAMPs such as calprotectin (S100A8/9) have an established clinical role as a biomarker in IBD. In this review, we use IBD as an archetypal common chronic inflammatory disease to focus on the conceptual and evidential importance of DAMPs in pathogenesis and why DAMPs represent an entirely new class of targets for clinical translation.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1933-0219
1935-3456
DOI:10.1038/mi.2016.14